Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel Reports First Quarter 2021 Financial Results and Provides Business Update

View Press Release View All

Apr 28, 2021 • 7:30am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update

Apr 13, 2021 • 7:00am EDT

Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19

Apr 7, 2021 • 7:30am EDT

Rigel Announces Closing of Strategic Collaboration with Lilly

March 2021

View Presentation

2021 Annual Meeting of Stockholders

View Event Add to Calendar View All

Q1 2021

Quarter Ended Mar 31, 2021

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080